{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:02:10Z","timestamp":1791831730526,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Histone deacetylases (HDACs) are enzymes responsible for removing acetyl groups from histone proteins, resulting in chromatin condensation and the repression of genes. They regulate the expression of genes, the cell cycle, and multiple cellular processes. Hydroxamic acid is a well-recognized moiety characterized by its potent zinc-binding ability, making it an effective inhibitor of HDACs. A novel hydroxamic acid-based molecule, N\n                    <jats:sup>1<\/jats:sup>\n                    -(2,2\u2019-bipyridin-6-yl)-N\n                    <jats:sup>8<\/jats:sup>\n                    -hydroxyoctanediamide (compound 3B), was previously synthesized, and the anticancer properties of the compound were examined in vitro in our laboratory. No prior toxicological study has been performed on this compound. Therefore, the current investigation focused on the acute oral toxicity of compound 3B in female BALB\/c mice, adhering to OECD 423 guidelines. In this study, compound 3B was given orally at 300\u2009mg\/kg body weight (b.w.) or 2000\u2009mg\/kg b.w. The food consumption and body weight of the mice did not differ significantly between the control and treated groups. Variations were observed in the levels of a few of the biochemical markers. Histopathological examination revealed inflammatory infiltration and lesions in a few vital organs. The comprehensive investigation revealed that compound 3B exhibited moderate toxic effects at a relatively high dosage of 2000\u2009mg\/kg in few organs and caused alterations in biochemical markers; however, it did not result in any mortality, indicating that the LD\n                    <jats:sub>50<\/jats:sub>\n                    value exceeded 2000\u2009mg\/kg. Compound 3B can be administered at concentrations less than 2000\u2009mg\/kg for subsequent studies.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s40360-025-01040-9","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T17:45:20Z","timestamp":1764351920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vivo acute oral toxicity assessment of novel histone deacetylase 2 inhibitor"],"prefix":"10.1186","volume":"27","author":[{"given":"Padmini","family":"Pai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Savio","family":"D\u2019Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Oruganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapaettu","family":"Satyamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babitha Kampa","family":"Sundara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"1040_CR1","doi-asserted-by":"publisher","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Manyazewal T. New approaches and procedures for cancer treatment: current perspectives. Sage Open Med. 2021;9:20503121211034366.","journal-title":"Sage Open Med"},{"key":"1040_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/med.21505","volume":"38","author":"HM Hesham","year":"2018","unstructured":"Hesham HM, Lasheen DS, Abouzid KAM. Chimeric HDAC inhibitors: comprehensive review on the HDAC-based strategies developed to combat cancer. Med Res Rev. 2018;38:45\u201366.","journal-title":"Med Res Rev"},{"key":"1040_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ejmech.2017.05.016","volume":"136","author":"RG Fu","year":"2017","unstructured":"Fu RG, Sun Y, Sheng WB, Liao DF. Designing multi-targeted agents: an emerging anticancer drug discovery paradigm. Eur.J.Med.Chem. 2017;136:533\u201378.","journal-title":"Eur.J.Med.Chem"},{"key":"1040_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejmech.2017.10.021","volume":"143","author":"NM Raghavendra","year":"2018","unstructured":"Raghavendra NM, Pingili D, Kadasi S, Mettu A, Svum P. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur.J.Med.Chem. 2018;143:55\u201377.","journal-title":"Eur.J.Med.Chem"},{"key":"1040_CR5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/cancers13040634","volume":"13","author":"R Jenke","year":"2021","unstructured":"Jenke R, N R, Hansen FK, Aigner A, B\u00fcch T. Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives. Cancers. 2021;13:634.","journal-title":"Cancers"},{"key":"1040_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/0929867322666150416094720","volume":"22","author":"J Bian","year":"2015","unstructured":"Bian J, Zhang L, Han Y, Wang C, Zhang L. Histone deacetylase inhibitors: potent anti-leukemic agents. Curr Med Chem. 2015;22:22\u201340.","journal-title":"Curr Med Chem"},{"key":"1040_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","volume":"33","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhang J, Jiang Q, Zhang L, Song W. Zinc binding groups for histone deacetylase inhibitors. J. Enzym Inhib.Med.Chem. 2018;33:714\u201321.","journal-title":"J. Enzym Inhib.Med.Chem"},{"key":"1040_CR8","doi-asserted-by":"publisher","first-page":"810704","DOI":"10.3389\/fphar.2021.810704","volume":"12","author":"F Anwar","year":"2022","unstructured":"Anwar F, Saleem U, Rehman AU, Ahmad B, Ismail T, Mirza MU, Ahmad S. Acute oral, subacute, and developmental toxicity profiling of naphthalene 2-yl, 2-chloro, 5-nitrobenzoate: assessment based on stress response, toxicity, and adverse outcome pathways. Front Pharmacol. 2022;12:810704.","journal-title":"Front Pharmacol"},{"key":"1040_CR9","volume-title":"Guideline for testing of chemicals, guideline 423: acute oral toxicity-acute toxic class method 2001","author":"OECD","year":"2001","unstructured":"OECD. Guideline for testing of chemicals, guideline 423: acute oral toxicity-acute toxic class method 2001. 2001."},{"key":"1040_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7897\/2277-4343.1404130","volume":"14","author":"S Gothe","year":"2023","unstructured":"Gothe S, Pawade U, Nikam A, Anjankar M. OECD guidelines for acute oral toxicity studies: an overview. Int.J.Res. Ayurveda Pharm. 2023;14:137\u201340.","journal-title":"Int.J.Res. Ayurveda Pharm"},{"key":"1040_CR11","first-page":"11","volume":"47","author":"S Buitrago","year":"2008","unstructured":"Buitrago S, Martin TE, Tetens-Woodring J, Belicha-Villanueva A, Wilding GE. Safety and efficacy of various combinations of injectable anesthetics in BALB\/c mice. J Am Assoc Lab Anim Sci. 2008;47:11\u201317.","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"1040_CR12","first-page":"167","volume":"1","author":"J Soueid","year":"2015","unstructured":"Soueid J, Nokkari A, Makoukji J. Techniques and methods of animal brain surgery: perfusion, brain removal, and histological techniques. Taylor Francis. 2015;1:167\u201374.","journal-title":"Taylor Francis"},{"key":"1040_CR13","first-page":"S31","volume":"43","author":"WS Stokes","year":"2002","unstructured":"Stokes WS. Humane endpoints for laboratory animals used in regulatory testing. Ilar J. 2002;43:S31\u201338.","journal-title":"Ilar J"},{"key":"1040_CR14","first-page":"1","volume":"1","author":"P Pai","year":"2025","unstructured":"Pai P, Reddy Y, Das I, Venkidesh BS, Bhandari P, Rao P, Oruganti S, Prasad K, Shetty MG, Satyamoorthy K, Sundara BK. Targeting neuroblastoma with hydroxamic acid based HDAC1 and HDAC2 inhibitors: insights from in vitro and in vivo studies. Investigational New Drugs. 2025;1:1\u201312.","journal-title":"Investigational New Drugs"},{"key":"1040_CR15","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.3390\/foods12224111","volume":"12","author":"J Liu","year":"2023","unstructured":"Liu J, Yao Y, Cheng Y, Hua W, Zhu X, Miao Q, Huang G, Mi S, Ruan R. Acute oral toxicity evaluation of almond hull powders in BALB\/c mice. Foods. 2023;12:4111.","journal-title":"Foods"},{"key":"1040_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00210-019-01742-y","volume":"393","author":"O Bedi","year":"2020","unstructured":"Bedi O, Krishan P. Investigations on acute oral toxicity studies of purpurin by application of OECD guideline 423 in rodents. n-S Arch Pharmacol. 2020;393:565\u201371.","journal-title":"n-S Arch Pharmacol"},{"key":"1040_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43141-022-00422-4","volume":"20","author":"HM Ahmed","year":"2022","unstructured":"Ahmed HM, Shehata HH, Gs E-S, Abou Gabal HH, El-Daly SM. Ameliorative effect of lactobacillus rhamnosus gg on acetaminophen-induced hepatotoxicity via PKC\/Nrf2\/PGC-1\u03b1 pathway. J Genet Eng Biotechnol. 2022;20:1\u201314.","journal-title":"J Genet Eng Biotechnol"},{"key":"1040_CR18","doi-asserted-by":"crossref","unstructured":"Yang X, Schnackenberg LK, Shi Q, Salminen WF. Hepatic toxicity biomarkers. Biomarker In Toxicol. 2014;241\u201359.","DOI":"10.1016\/B978-0-12-404630-6.00013-0"},{"key":"1040_CR19","unstructured":"Lala V, Zubair M, Minter D. Liver function tests. StatPearls. 2023."},{"key":"1040_CR20","first-page":"8","volume":"26","author":"M Karin","year":"2014","unstructured":"Karin M, Bevanda M, Babi\u0107 E, Mimica M, Bevanda-Glibo D, Volari\u0107 M, Pravdi\u0107 D. Correlation between biochemical and histopathological parameters in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Psychiatr Danub. 2014;26:8\u201313.","journal-title":"Psychiatr Danub"},{"key":"1040_CR21","unstructured":"Chapman K. Challenging the regulatory requirement for acute toxicity studies in the development of new medicines. National Centre for the Replacement, Refinement and Reduction of Animals in Research workshop report. 2007, pp. 1998\u20132003 (Vol. 7, pp. 1998-2003)."},{"key":"1040_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.yrtph.2007.11.009","volume":"50","author":"S Robinson","year":"2008","unstructured":"Robinson S, Delongeas JL, Donald E, Dreher D, Festag M, Kervyn S, Chapman K. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul Toxicol Pharmacol. 2008;50:345\u201352.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1040_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/toxsci\/kfac042","volume":"188","author":"AL Karmaus","year":"2022","unstructured":"Karmaus AL, Mansouri K, To KT, Blake B, Fitzpatrick J, Strickland J, Kleinstreuer N. Evaluation of variability across rat acute oral systemic toxicity studies. Toxicological Sci. 2022;188:34\u201347.","journal-title":"Toxicological Sci"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01040-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-01040-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-01040-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:04:00Z","timestamp":1767474240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-025-01040-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1040"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-01040-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6988823\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Institutional Animal Ethics Committee of Kasturba Medical College, Manipal Academy of Higher Education, Manipal (IAEC\/KMC\/46\/2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that a provisional patent application (Application Number: 202441019540.) has been filed related to the chemical compound discussed in this research. Manasa Gangadhar Shetty, Padmini Pai, Babitha Kampa Sundara, Kapaettu Satyamoorthy and Srinivas Oruganti are listed as an inventors on the patent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"3"}}